Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial

• Main Authors: Carlo Buonerba (Author), Pietro De Placido (Author), Dario Bruzzese (Author), Martina Pagliuca (Author), Paola Ungaro (Author), Davide Bosso (Author), Dario Ribera (Author), Simona Iaccarino (Author), Luca Scafuri (Author), Antonietta Liotti (Author), Valeria Romeo (Author), Michela Izzo (Author), Francesco Perri (Author), Beniamino Casale (Author), Giuseppe Grimaldi (Author), Francesca Vitrone (Author), Arturo Brunetti (Author), Daniela Terracciano (Author), Alfredo Marinelli (Author), Sabino De Placido (Author), Giuseppe Di Lorenzo (Author)
• Format: Book
• Published: Frontiers Media S.A., 2018-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on-and off-target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue m...